DRMA - Dermata Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-4.979M

Cash

8.767M

Avg Qtr Burn

-1.969M

Short % of Float

3.35%

Insider Ownership

28.94%

Institutional Own.

1.02%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DMT310 Details Acne vulgaris, Acne	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DMT310 Details Psoriasis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DMT310 Details Papulopustular rosacea	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.